Vol 15, No 1 (2020)
Conference report / Report
Published online: 2020-02-27
Not only ISCHEMIA — report from AHA Scientific Sessions, Philadelphia, 16–18 November 2019
1
, 1
, 1
DOI: 10.5603/FC.2020.0011
Folia Cardiologica 2020;15(1):84-87.
Abstract
Not available
Keywords: clinical trialscoronary artery diseaseheart failurerisk factors
References
- Hochman JS, Reynolds HR, Bangalore S, et al. ISCHEMIA Research Group. Baseline characteristics and risk profiles of participants in the ISCHEMIA randomized clinical trial. JAMA Cardiol. 2019; 4(3): 273–286.
- Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020; 141(2): 90–99.
- Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381(26): 2497–2505.
- German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020; 34(1): 1–9.
- Ray KK, Nicholls SJ, Ginsberg HD, et al. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019; 217: 72–83.
- Mehran R, Cao D, Baber U, et al. Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thromb Haemost. 2014; 112(5): 1069–1070.
